83151-31-9

Upstream product

• 1189-71-5 isocyanate de chlorosulfonyle 
• 142-29-0 cyclopentene 

Downstream Products

• 125910-65-8 (1S,5R)-7-Oxo-6-aza-bicyclo[3.2.0]heptane-6-carboxylic acid (4-chloro-phenyl)-amide 
• 57043-00-2 (1RS,2SR)-cispentacin 
• 57043-01-3 (+/-)-trans-2-amino-cyclopentane carboxylic acid 
• 39155-94-7 (1R,5S)-6-azabicyclo[3.2.0]heptan-7-one 
• 122672-46-2 (-)-cispentacin 
• 39155-95-8 (1S,5R)-6-azabicyclo<3.2.0>heptan-7-one 
• 128052-92-6 (+)-(1S,2R)-2-aminocyclopentane-1-carboxylic acid hydrochloride 
• 119993-56-5 cis-2-aminocyclopentanecarboxylic acid ethyl ester hydrochloride 
• 128052-92-6 (±)-cis-2-aminocyclopentane-1-carboxylic acid hydrochloride 
• 282524-97-4 Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid 
• 38052-23-2 ethyl cis-2-amino-1-cyclopentane-carboxylate 
• 282524-97-4 (1R,2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}cyclopentanecarboxylic acid 
• 1203556-26-6 (1S,2R)-Fmoc-2-amino-1-cyclopentanecarboxylic acid 
• 128668-90-6 (4aR,7aS)-3-(3-Chloro-phenyl)-hexahydro-cyclopentapyrimidine-2,4-dione 

Relevant academic research and scientific papers

Large-scale syntheses of FMOC-protected non-proteogenic amino acids: Useful building blocks for combinatorial libraries

Convenient and reliable large-scale procedures for the protection of various amino acids with N-(9-fluorenylmethoxycarbonyl)oxysuccinimide (FMOC-OSu) are described. Commercially available 4-aminomethylbenzoic acid and trans-4-(aminomethyl)cyclohexanecarbo

SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF

Compounds of formula (I), processes for their production and their use as pharmaceuticals.

Nylon-3 polymers that enable selective culture of endothelial cells

Substrates that selectively encourage the growth of specific cell types are valuable for the engineering of complex tissues. Some cell-selective peptides have been identified from extracellular matrix proteins; these peptides have proven useful for biomat

Hairpin folding behavior of mixed α/β-peptides in aqueous solution

The invention of new strategies for the design of protein-mimetic oligomers that manifest the folding encoded in natural amino acid sequences is a significant challenge. In contrast to the α-helix, mimicry of protein β-sheets is less understood. We report

New compounds

The present invention encompasses compounds of general formula (1) wherein R1, R2, R4, X, m, n and p are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

Efficient synthesis of (1R,2S) and (1S,2R)-2-aminocyclopentanecarboxylic acid ethyl ester derivatives in enantiomerically pure form

A 4-step synthesis of an optically active synthetic intermediate [(1R,2S)-2-(4′-fluorobenzylamino)cyclopentanecarboxylic acid ethyl ester complex with (S)-(+)-mandelic acid; compound 12, >99% de] required for the preparation of a promising HCV NS5B polymerase inhibitor is reported. This process utilizes mandelic acid as a resolving agent, which can be recovered in good yield by a simple extraction. An optimized version of the chemistry described avoids the use of chromatographic purifications making it suitable for large-scale applications. In addition, the straightforward conversion of compound 12 to enantiomerically pure (1R,2S)-2-aminocyclopentanecarboxylic acid ethyl ester and the corresponding Boc and Cbz derivatives is reported. The preparation of the enantiomer of 12 (compound 15) in enantiomerically pure form and the conversion of this entity to (1S,2R)-2-aminocyclopentanecarboxylic acid ethyl ester and the corresponding Boc and Cbz derivatives is also described.

Synthesis and antimalarial evaluation of cyclic β-amino acid-containing dipeptides

This paper describes an efficient synthesis and the antiparasitic evaluation of cyclic β-amino acid-containing dipeptides 3.1-3.6 and 4.1-4.5. The antimalarial properties of all these dipeptides have been evaluated in vitro against Plasmodium falciparum a

NEW COMPOUNDS

The present invention encompassescompounds of general formula (1) wherein R1 to R4 , X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised byexcessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

2,4-diamino-pyrimidines as aurora inhibitors

The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

Design, synthesis and biological evaluation of novel bicyclic β-lactams as potential antimalarials

A series of bicyclic N-substituted and unsubstituted β-lactams were synthesized and evaluated as targeted potential antimalarials. The compounds MNR4 and MNR5 were found to have highest potency against Plasmodium falciparum in vitro.